Multisistemik İnflamatuvar Sendrom (MIS-C) Olgularının Klinik Özelliklerinin ve Kardiyolojik Bulgularının Değerlendirilmesi

Öz

Çocuklarda multisistemik inflamatuvar sendrom (MIS-C), COVID-19 enfeksiyonu sonrası gelişen, çoklu organ tutulumuyla giden hiperinflamasyonla karakterize bir hastalık tablosudur. Bu çalışmada, MIS-C olgularının klinik özelliklerinin, kardiyolojik bulgularının ve kardiyak manyetik rezonans görüntüleme (MRG) sonuçlarının değerlendirilmesi amaçlanmıştır. Çalışmaya Eskişehir Osmangazi Üniversitesi Tıp Fakültesi’nde, Kasım 2020-Haziran 2022 tarihleri arasında takip edilen MIS-C tanılı 31 olgu dahil edildi. Olguların klinik, epidemiyolojik özellikleri ve kardiyolojik bulguları retrospektif olarak değerlendirildi. Çalışmaya dahil edilen 31 olgunun 17’si (%55) erkek, 14’ü (%45) kız idi. Yaş ortalaması 102 (2-204) ay idi. En sık başvuru semptomları sırasıyla ateş, döküntü, konjunktivit ve karın ağrısıydı. En sık kardiyolojik bulgular ise; sol ventrikül disfonksiyonu, myokardit ve koroner dilatasyondu. Ağır kardiyolojik bulguları olan 8 olgunun 4'üne kardiyak MRG yapıldı, patolojik bulgu saptanmadı. Hipotansiyon ve şok bulguları olan, laboratuvar tetkiklerinde ferritin, D-dimer, IL-6 yüksekliği olan, ekokardiyografide sol ventrikül disfonksiyonu ve myokardit bulguları olan hastaların, yoğun bakım yatış oranları daha yüksekti. Kardiyovasküler tutulumun derecesi hastalığın takibinde ve tedavi rejiminin belirlenmesinde önemlidir. Olası kalıcı kardiyak hasar açısından tüm hastalar ekokardiyografi ve kardiyak MRG ile izlenmelidir. MIS-C ciddi, yaşamı tehdit eden kardiyak belirtilere yol açabilse de, erken tanı ve uygun tedavi gelecekte ciddi kardiyak morbidite ve mortalite riskini önleyebilir.

Anahtar Kelimeler

• MIS-C
• pediatrik
• ekokardiyografi
• MR

Evaluation of Multisystem Inflammatory Syndrome in Children (MIS-C) Cases: Clinical Features and Cardiologic Findings

Öz

 Multisystem inflammatory syndrome in children (MIS-C) is a disease characterized by hyperinflammation with multiple organ involvement that develops after COVID-19 infection. In this study, we aimed to assess the clinical characteristics, cardiologic findings, and cardiac magnetic resonance imaging (MRI) results of MIS-C cases. Thirty-one patients diagnosed with MIS-C and followed up at Eskişehir Osmangazi University Faculty of Medicine between November 2020 and June 2022 were included in the study. The clinical and epidemiological characteristics and cardiological findings of the patients were evaluated retrospectively. Fifty-five percent of the thirty-one MIS-C cases were male and the mean age was 102 (2-204) months. The most common presenting symptoms were fever, rash, conjunctivitis, and abdominal pain. The most common cardiac findings were left ventricular dysfunction, myocarditis, and coronary artery dilatation. Cardiac MRI was performed in 4 of 8 patients with severe cardiac findings, and no pathologic findings were noted. Patients who had hypotension and cardiogenic shock at the time of admission, who had high ferritin, D-dimer, and IL -6 levels on laboratory tests, and who had left ventricular dysfunction and myocarditis on echocardiography had a high rate of ICU admission. The degree of cardiovascular involvement is important in following up on the disease and determining the treatment regimen. All patients should be monitored by echocardiography and cardiac MRI for possible permanent cardiac damage. Although MIS-C can lead to serious, life-threatening cardiac manifestations, early diagnosis and appropriate treatment can prevent the risk of serious cardiac morbidity and mortality in the future.

Anahtar Kelimeler

• MIS-C
• cardiac involvement
• cardiac MRI
• echocardiography

Kaynakça

1. 1. Dong Y, Mo X, Hu Y et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics 2020; 145: e20200702
2. 2. World Health Organization. Corona virüs disease 2019 (COVID-19) situation reports; 2021. [Cited: 19 May 2021] Available from URL: https://wwwwhoint/emergencies/diseases/novel-coronavirus-2019/situation-reports.
3. 3. Whittacker E, Bamford A, Kenny J et al (2020) Clinical characteristics of 58 children with a pediatri cinflammatory multisystem syndrom etemporallyas sociated with SARS-CoV-2. JAMA 324:259–269.
4. 4. Riphagen S, Gomez X, Gonzalez-Martinez C et al. Hyper inflammatory shock in children during COVID-19 pandemic. Lancet 2020; 23: 1607–8.
5. 5. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasakilike disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 2020;395:1771–1778.
6. 6. Dufort EM, Koumans EH, Chow EJ et al (2020) Multisystem inflammatory syndrome in children in New York State. N Engl J Med 383:347–358.
7. 7. Feldstein LR, Rose EB, Horwitz SM et al (2020) Multisystem inflammatory syndrome in U.S. children andadolescents. N Engl J Med 383:334–346.
8. 8. 8. Centers for Disease Control and Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with corona virus disease 2019 (COVID-19). https://emergency.cdc.gov/han/2020/han00432.asp (3 August 2021,date lastaccessed).

9. 9. World Health Organization. Multisystem inflammatory syndrome in children and adolescentstemporallyrelatedto COVID-19 (2020), WHO reference number:WHO/2019 nCoV/Sci_Brief/Multisystem_Syndrome_Children/2020.1https://www.who.int/news-room/ commentaries/detail/multisystem-inflammatory-syndrome-in-children-and adolescents with-covid-19 (3August 2021,date lastaccessed).
10. 10. Valverde I, Singh Y, Sanchez-de-Toledoet al. Acute Cardiovascular Manifestations in 286 Children With Multisystem Inflammatory Syndrome Associated With COVID-19 Infection in Europe. Circulation.2021 Jan 5;143(1):21-32.
11. 11. Abrams JY, Oster ME, Godfred-Cato SE, et al.Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study. Lancet Child Adolesc Health. 2021;5:323-331.
12. 12. Yilmaz Ciftdogan D, Ekemen Keles Y,Cetin BS, et al. COVID-19 associated multisystem icinflammatory syndrome in 614 children with and with out over lap with Kawasaki disease-Turk MIS-C study group. Eur J Pediatr. 2022;181:2031-2043.
13. 13. Torres JP, Izquierdo G, Acu~na M, et al. Multisystem inflammatory syndrome in children (MIS-C): report of the clinicaland epidemiological characteristics of cases in Santiago de Chiled uring the SARS-CoV-2 pandemic. Int J Infect Dis 2020;100:75–81.
14. 14. Kıymet E, Böncüoğlu E, Şahinkaya Ş, et al. A Comparative Study of Children with MIS-C between Admitted to the Pediatric Intensive Care Unitand Pediatric Ward: A One-Year Retrospective Study. J Trop Pediatr. 2021;8:67
15. 15. Yilmaz Cift dogan D, Ekemen Keles Y, Karbuz A, et al. Multisystem inflammatory syndrome in children associated with COVID-19 in 101 cases from Turkey (Turk-MISC study). J Paediatr Child Health. 2022 58:1069-1078.
16. 16. Sözeri B, Çağlayan Ş, Atasayan V, et al. The clinical course and short-term health out comes of multisystem inflammatory syndrome in children in the single pediatric rheumatology center. Postgrad Med. 2021;133:994-1000.
17. 17. Tekin ZE, Sezer M, Çelikel E, et al. Factor saffecting diseases everity of multisystem inflammatory syndrome in children. Pamukkale Medical Journal. 2022: 15:595-602.
18. 18. Miller AD, Zambrano LD, Yousaf AR, et al. Multisystem inflammatory syndrome in children-united states, february 2020-July 2021. Clin Infect Dis 2021:ciab1007.
19. 19. Chiotos K, Bassiri H, Behrens EM, et al. Multisystem inflammatory syndrome in children during the coranavirus 2019 pandemic: a caseseries. J Pediatric Infect Dis Soc 2020;9:393-398.
20. 20. Radia T, Williams N, Agrawal P, et al. Multi-system inflammatory syndrome in children&adolescents (MIS-C): a system aticreview of clinical feature sandpre sentation. Paediatr Respir Rev 2021;38:51-57.
21. 21. Kavurt AV, Bağrul D, Gül AEK, Özdemiroğlu N, et al. Echocardiographic Findingsand Correlation with Laboratory Values in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19. Pediatr Cardiol. 2022 Feb;43(2):413-425.
22. 22. Arslan SY, Bal ZS, Bayraktaroglu S, et al. Cardiac Assessment in Children with MIS-C: Late Magnetic Resonance Imaging Features. Pediatr Cardiol. 2022; 2:1–10.
23. 23. Cetin BS, Kısaarslan AP, Tekin S,et al. Evaluation of Baseline Characteristics and Prognostic Factors in Multisystemic Inflammatory Syndrome in Children: Is It Possibleto Foresee the Prognosis in the First Step? J ClinMed. 2022;11:4615.
24. 24. Henderson LA, Canna SW, Friedman KG, et al. AmericanCollege of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. Arthritis Rheumatol. 2021;73:e13-e29.
25. 25. Capone CA, Misra N, Ganigara M et al (2021) Sixmonth follow up of patients with multi-system inflammatory syndrome in children. Pediatrics 148:e2021050973.
26. 26. Caro-Domínguez P, Navallas M, Riaza-Martin L et al. Imaging findings of multisystem inflammatory syndrome in children associated with COVID-19. Pediatr Radiol 51:1608–1620